Further, IKK inhibitor VII is able to potentiate cell killing in conjunction with doxorubicin and vincristine in human and canine B-cell lymphoma by inhibiting NF-κB activation as well as IKK-dependent NF-κB-independent pathways. This evidence concerns the gene NFKB1 and B-cell non-Hodgkin lymphoma.